Evidence map›Paper›PMID 39666193›Full record

ArticleAnnals of surgical oncology2025

Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An International Multicenter Study.

Joseph R Habib, Ammar A Javed, Ingmar F Rompen, Camila Hidalgo Salinas, Anthony Sorrentino, Brady A Campbell, Paul C M Andel, Vincent P Groot, Kelly J Lafaro, Greg D Sacks and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026
    Article
  2. A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Observational
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Joseph R HabibDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Ammar A JavedDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Ingmar F RompenDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Camila Hidalgo SalinasDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Anthony SorrentinoDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Brady A CampbellDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Paul C M AndelDepartment of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center and St. Antonius Hospital Nieuwegein, Utrecht, The Netherlands.
Vincent P GrootDepartment of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center and St. Antonius Hospital Nieuwegein, Utrecht, The Netherlands.
Kelly J LafaroDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Greg D SacksDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Adrian T BilleterUniversity of Basel, Clarunis University Digestive Health Care Center, Basel, Switzerland.
I Quintus MolenaarDepartment of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center and St. Antonius Hospital Nieuwegein, Utrecht, The Netherlands.
Beat P Müller-StichUniversity of Basel, Clarunis University Digestive Health Care Center, Basel, Switzerland.
Marc G BesselinkAmsterdam UMC, Department of Surgery, University of Amsterdam, Amsterdam, The Netherlands.
Jin HeDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Christopher L WolfgangDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Lois A DaamenDepartment of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center and St. Antonius Hospital Nieuwegein, Utrecht, The Netherlands. L.A.Daamen-3@umcutrecht.nl.

Funding

Research Training for Physician-Scientists in Gastrointestinal OncologyT32CA193111 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BAR-SAGI, DAFNA, WOLFGANG, CHRISTOPHER L. · 2015 to 2024
$2.7M
National Institute of Health T32CA193111NCI NIH HHS T32 CA193111
6 · The paper itself

Abstract

backgroundEarly recurrence in intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) is poorly defined. Predictors are lacking and needed for patient counseling, risk stratification, and postoperative management. This study aimed to define and predict early recurrence for patients in resected IPMN-derived PDAC and guide management.

methodsA lowest p value for survival after recurrence (SAR) was used to define early recurrence in resected IPMN-derived PDAC from five international centers. Overall survival (OS) and SAR were compared using log-rank tests. A multivariable logistic regression identified odds ratios (ORs) with 95 % confidence intervals (CIs) for early recurrence. Rounded ORs were used to stratify patients into low-, intermediate-, and high-risk groups using upper and lower quartile score distributions. Adjuvant chemotherapy was assessed by Cox regression and log-rank tests for OS in risk groups.

resultsRecurrence developed in 160 (42 %) of 381 patients. Early recurrence was defined at 10.5 months and observed in 61 patients (38 % of recurrences). The median SAR for the patients with early recurrence was 8.3 months (95 % CI, 3.1-16.1 months) compared with 12.9 months (95 % CI, 5.2-27.5 months) for the patients with late recurrence. The independent predictors of early recurrence were CA19-9 (OR, 3.80; 95 % CI, 1.54-9.41) and N2 disease (OR, 7.29; 95 % CI, 3.22-16.49). The early recurrence rates in the low-, intermediate-, and high-risk groups were respectively 1 %, 14 %, and 32 %. Adjuvant chemotherapy was associated with improved OS only for the high-risk patients (hazard ratio, 0.50; 95 % CI, 0.32-0.79).

conclusionIn IPMN-derived PDAC, the optimal cutoff for early recurrence is 10.5 months. Both CA19-9 and N stage predict early recurrence. Adjuvant chemotherapy is associated with survival benefit only for high-risk patients.

Indexed as

Adenocarcinoma, MucinousCarcinoma, Pancreatic DuctalNeoplasm Recurrence, LocalPancreatic Intraductal NeoplasmsPancreatic NeoplasmsAgedAged, 80 and overChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansMaleMiddle AgedPancreatectomyPrognosisRetrospective StudiesEarly recurrenceIntraductal papillary mucinous neoplasmInvasive IPMNPancreatic cancerPancreatic neoplasmsRecurrence

Identifiers

PMID39666193
PMCPMC12958335

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.